ginsenoside rh2 has been researched along with Pancreatic Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fagone, P; He, J; Li, Q; Li, S; Lu, Y; Nicoletti, F; Tian, C; Xiang, M; Yang, J; Yuan, H | 1 |
| Fang, CY; Liang, ZH; Tang, GD; Tang, XP; Zhang, LY | 1 |
2 other study(ies) available for ginsenoside rh2 and Pancreatic Neoplasms
| Article | Year |
|---|---|
The combination of gemcitabine and ginsenoside Rh2 enhances the immune function of dendritic cells against pancreatic cancer via the CARD9-BCL10-MALT1 / NF-κB pathway.
Topics: Animals; B-Cell CLL-Lymphoma 10 Protein; CARD Signaling Adaptor Proteins; Cell Line, Tumor; Dendritic Cells; Gemcitabine; Immunity; Mice; Mucosa-Associated Lymphoid Tissue Lymphoma Translocation 1 Protein; NF-kappa B; Pancreatic Neoplasms; Tumor Microenvironment | 2023 |
Effects of ginsenoside Rh2 on growth and migration of pancreatic cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Apoptosis Regulatory Proteins; Cell Cycle Checkpoints; Cell Movement; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Ginsenosides; Humans; Neoplasm Invasiveness; Pancreatic Neoplasms; Signal Transduction; Time Factors | 2013 |